AOA Dx

AOA Dx develops blood-based tests for early detection of ovarian cancer built on gangliosides and other glycolipid biomarkers combined with proteins and machine learning. Its first product candidate, AKRIVIS GD, is intended to distinguish malignant from benign adnexal masses and detect early-stage disease; the company has presented performance data at gynaecologic oncology meetings and holds FDA breakthrough device designation for a version of the test. It has raised seed and Series A financing; amounts are not recorded here because no primary source was fetched.